Darmstadt, Germany-based Merck KGaA has dropped the candidate oncology drug evofosfamide following two Phase 3 studies that failed to show efficacy in patients with advanced soft tissue sarcoma and advanced pancreatic cancer. ---Subscribe to MedNous to access this article--- Clinical Research Company News
